Literature DB >> 11106549

Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression.

M E Kupferman1, M E Fini, W J Muller, R Weber, Y Cheng, R J Muschel.   

Abstract

Matrix metalloproteinase 9 (MMP-9, also known as gelatinase B or 92-kd Type IV collagenase) is overexpressed in many human and murine cancers. We induced carcinomas in mice carrying a transgene that links the MMP-9 promoter to the reporter ss-galactosidase so that activation of the MMP-9 promoter would be indicated by ss-galactosidase. Mammary carcinomas were induced by mating the MMP-9 promoter reporter transgenic mice with mice carrying a transgene for murine mammary tumor virus promoter linked to polyoma middle T antigen, a transgene that leads to rapid development of mammary tumors in female mice. None of the hyperplastic mammary glands and none of the carcinomas in situ expressed ss-galactosidase. However, all invasive tumors had evidence of ss-galactosidase expression. In addition to the breast carcinomas, a malignant teratoma in a female and a papillary adenocarcinoma in the pelvic region of a male arose and were also ss-galactosidase positive. We also induced skin tumors in the mice with the MMP-9 reporter transgene with 7, 12-dimethylbenz[a]anthracene (DMBA) treatment followed by phorbol 12 myristate 13-acetate (TPA). None of the papillomas or in situ carcinomas showed any ss-galactosidase expression, but expression was seen in invasive carcinoma. Although normal skin epithelial cells did not express ss-galactosidase, we did find staining in a few cells at the duct of the sebaceous gland at the base of the hair follicles. The MMP-9 reporter transgene did not lead to expression in the alveolar macrophages, confirming that additional upstream sequences are required for expression in macrophages. These experiments have revealed that MMP-9 promoter activity is induced coincident with invasion during tumor progression. Furthermore, this indicates that the more proximal upstream elements of the promoter are sufficient for MMP-9 transcription during tumor progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106549      PMCID: PMC1885751          DOI: 10.1016/S0002-9440(10)64815-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

1.  Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression.

Authors:  S Y Rha; J H Kim; J K Roh; K S Lee; J S Min; B S Kim; H C Chung
Journal:  Breast Cancer Res Treat       Date:  1997-04       Impact factor: 4.872

2.  Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma.

Authors:  G Sehgal; J Hua; E J Bernhard; I Sehgal; T C Thompson; R J Muschel
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

3.  Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas.

Authors:  J L Jones; P Glynn; R A Walker
Journal:  J Pathol       Date:  1999-10       Impact factor: 7.996

4.  Defective trophoblast function in mice with a targeted mutation of Ets2.

Authors:  H Yamamoto; M L Flannery; S Kupriyanov; J Pearce; S R McKercher; G W Henkel; R A Maki; Z Werb; R G Oshima
Journal:  Genes Dev       Date:  1998-05-01       Impact factor: 11.361

5.  Tumor cell contact mediated transcriptional activation of the fibroblast matrix metalloproteinase-9 gene: involvement of multiple transcription factors including Ets and an alternating purine-pyrimidine repeat.

Authors:  B P Himelstein; E J Lee; H Sato; M Seiki; R J Muschel
Journal:  Clin Exp Metastasis       Date:  1998-02       Impact factor: 5.150

6.  Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.

Authors:  M A Sovak; R E Bellas; D W Kim; G J Zanieski; A E Rogers; A M Traish; G E Sonenshein
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

7.  Different expression patterns of MMP-2 and MMP-9 in breast cancer.

Authors:  S Y Rha; W I Yang; J H Kim; J K Roh; J S Min; K S Lee; B S Kim; H C Chung
Journal:  Oncol Rep       Date:  1998 Jul-Aug       Impact factor: 3.906

8.  Gelatinase B/lacZ transgenic mice, a model for mapping gelatinase B expression during developmental and injury-related tissue remodeling.

Authors:  R Mohan; W B Rinehart; P Bargagna-Mohan; M E Fini
Journal:  J Biol Chem       Date:  1998-10-02       Impact factor: 5.157

9.  The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor.

Authors:  T Watabe; K Yoshida; M Shindoh; M Kaya; K Fujikawa; H Sato; M Seiki; S Ishii; K Fujinaga
Journal:  Int J Cancer       Date:  1998-07-03       Impact factor: 7.396

10.  Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.

Authors:  A G Remacle; A Noël; C Duggan; E McDermott; N O'Higgins; J M Foidart; M J Duffy
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

View more
  25 in total

Review 1.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

2.  Human leucine zipper protein sLZIP induces migration and invasion of cervical cancer cells via expression of matrix metalloproteinase-9.

Authors:  Hyereen Kang; Sung-Wuk Jang; Jesang Ko
Journal:  J Biol Chem       Date:  2011-10-18       Impact factor: 5.157

3.  An immortalization-dependent switch in integrin function up-regulates MMP-9 to enhance tumor cell invasion.

Authors:  John M Lamar; Kevin M Pumiglia; C Michael DiPersio
Journal:  Cancer Res       Date:  2008-09-15       Impact factor: 12.701

4.  Treatment of eyelid epithelial neoplasm by targeting sonic hedgehog signaling: an experimental study.

Authors:  Ken-Ichi Miyazaki; Shizuya Saika; Osamu Yamanaka; Yuka Okada; Yoshitaka Ohnishi
Journal:  Jpn J Ophthalmol       Date:  2006 Jul-Aug       Impact factor: 2.447

5.  Expression of MMP-9 and WAVE3 in colorectal cancer and its relationship to clinicopathological features.

Authors:  Yi Zhang; Xiao-Ya Guan; Bin Dong; Min Zhao; Jian-Hui Wu; Xiu-Yun Tian; Chun-Yi Hao
Journal:  J Cancer Res Clin Oncol       Date:  2012-07-18       Impact factor: 4.553

6.  An orthotopic model of lung cancer to analyze primary and metastatic NSCLC growth in integrin alpha1-null mice.

Authors:  Xiwu Chen; Yan Su; Barbara Fingleton; Heath Acuff; Lynn M Matrisian; Roy Zent; Ambra Pozzi
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

Review 7.  Matrix metalloproteinases and their clinical relevance in urinary bladder cancer.

Authors:  Tibor Szarvas; Frank vom Dorp; Süleyman Ergün; Herbert Rübben
Journal:  Nat Rev Urol       Date:  2011-04-12       Impact factor: 14.432

8.  Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background.

Authors:  Michelle D Martin; Kathy J Carter; Sharon R Jean-Philippe; Mayland Chang; Shahriar Mobashery; Sophie Thiolloy; Conor C Lynch; Lynn M Matrisian; Barbara Fingleton
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

9.  Transgenic mice demonstrate novel promoter regions for tissue-specific expression of the urokinase receptor gene.

Authors:  Heng Wang; John Hicks; Parham Khanbolooki; Sun-Jin Kim; Chunhong Yan; Yao Wang; Douglas Boyd
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

10.  Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation.

Authors:  Franco Capozza; Terence M Williams; William Schubert; Steve McClain; Boumediene Bouzahzah; Federica Sotgia; Michael P Lisanti
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.